As of the latest Form 4 filed Jun 18, 2026.
What Stoke Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 31 most recent filings for STOK.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-18 | 2026-06-16 | Allan Jonathan GENERAL COUNSEL & CORP SEC | SSale | −1.46K | $29.95 | $43.6K | Yes (planned) | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Ticho Barry CHIEF MEDICAL OFFICER | SSale | −1.79K | $30.58 | $54.9K | Yes (planned) | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Allan Jonathan GENERAL COUNSEL & CORP SEC | SSale | −601.00 | $34.41 | $20.7K | Yes (planned) | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Allan Jonathan, GENERAL COUNSEL & CORP SEC | SSale | −8.69K | $33.64 | $292K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-19 | Ticho Barry CHIEF MEDICAL OFFICER | SSale | −1.46K | $29.99 | $43.8K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-19 | Ticho Barry, CHIEF MEDICAL OFFICER | MExercise | +1.36K | $2.19 | $2.99K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Allan Jonathan GENERAL COUNSEL & CORP SEC | SSale | −72.00 | $32.85 | $2.37K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Allan Jonathan, GENERAL COUNSEL & CORP SEC | SSale | −334.00 | $31.79 | $10.6K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Allan Jonathan, GENERAL COUNSEL & CORP SEC | SSale | −4.22K | $31.28 | $132K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Ticho Barry CHIEF MEDICAL OFFICER | SSale | −103.00 | $32.85 | $3.38K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Ticho Barry, CHIEF MEDICAL OFFICER | SSale | −483.00 | $31.79 | $15.4K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Ticho Barry, CHIEF MEDICAL OFFICER | SSale | −6.10K | $31.28 | $191K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Leggett Thomas Chief Financial Officer | SSale | −37.00 | $32.85 | $1.22K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Leggett Thomas, Chief Financial Officer | SSale | −172.00 | $31.79 | $5.47K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Leggett Thomas, Chief Financial Officer | SSale | −2.17K | $31.28 | $68.0K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Hoitt Jason Chief Patient Officer | SSale | −30.00 | $32.85 | $985.50 | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Hoitt Jason, Chief Patient Officer | SSale | −139.00 | $31.79 | $4.42K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-18 | Hoitt Jason, Chief Patient Officer | SSale | −1.76K | $31.28 | $55.1K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Allan Jonathan GENERAL COUNSEL & CORP SEC | SSale | −1.79K | $33.38 | $59.8K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Allan Jonathan, GENERAL COUNSEL & CORP SEC | SSale | −2.48K | $32.74 | $81.1K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Ticho Barry CHIEF MEDICAL OFFICER | SSale | −2.59K | $33.38 | $86.3K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Ticho Barry, CHIEF MEDICAL OFFICER | SSale | −3.58K | $32.74 | $117K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Leggett Thomas Chief Financial Officer | SSale | −922.00 | $33.38 | $30.8K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Leggett Thomas, Chief Financial Officer | SSale | −1.27K | $32.74 | $41.7K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Hoitt Jason Chief Patient Officer | SSale | −748.00 | $33.38 | $25.0K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Hoitt Jason, Chief Patient Officer | SSale | −1.03K | $32.74 | $33.8K | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Allan Jonathan GENERAL COUNSEL & CORP SEC | SSale | −2.68K | $32.61 | $87.3K | Yes (planned) | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Allan Jonathan, GENERAL COUNSEL & CORP SEC | SSale | −1.30K | $31.60 | $41.1K | Yes (planned) | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Kaye Edward M. MD Director | SSale | −1.33K | $33.10 | $44.1K | Yes (planned) | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Kaye Edward M. MD, Director | SSale | −8.27K | $32.52 | $269K | Yes (planned) | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Kaye Edward M. MD, Director | SSale | −3.83K | $31.44 | $120K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also STOK’s full analysis or the market-wide insider trading feed. The tabs above jump to STOK’s other SEC data.
Source: SEC Form 4 filings for STOK, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.